111 related articles for article (PubMed ID: 34725641)
1. Corrigendum to "PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer".
Li G; Liu G; Wang X
Biomed Res Int; 2021; 2021():9762405. PubMed ID: 34725641
[TBL] [Abstract][Full Text] [Related]
2. PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer.
Li G; Wang X; Liu G
Biomed Res Int; 2021; 2021():5512340. PubMed ID: 34258263
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: A Weighted Gene Co-Expression Network Analysis-Derived Prognostic Model for Predicting Prognosis and Immune Infiltration in Gastric Cancer.
Chen Q; Tan Y; Zhang C; Zhang Z; Pan S; An W; Xu H
Front Oncol; 2021; 11():683333. PubMed ID: 33937088
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer.
Chen P; Gao Y; Ouyang S; Wei L; Zhou M; You H; Wang Y
Front Pharmacol; 2021; 12():. PubMed ID: 34512314
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation.
Xu F; Zhang J; Hu G; Liu L; Liang W
Cancer Cell Int; 2017; 17():54. PubMed ID: 28507454
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():751004. PubMed ID: 34531879
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: CDT1 is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
Front Oncol; 2021; 11():801970. PubMed ID: 34900749
[TBL] [Abstract][Full Text] [Related]
8. PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics.
Sheng X; Li Y; Li Y; Liu W; Lu Z; Zhan J; Xu M; Chen L; Luo X; Cai G; Zhang S
BMC Cancer; 2019 Aug; 19(1):840. PubMed ID: 31455288
[TBL] [Abstract][Full Text] [Related]
9. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection.
Noda T; Yamamoto H; Takemasa I; Yamada D; Uemura M; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Liver Int; 2012 Jan; 32(1):110-8. PubMed ID: 22098155
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer.
Deng L; Liang H; Han Y
Front Oncol; 2020; 10():582704. PubMed ID: 33224882
[TBL] [Abstract][Full Text] [Related]
11. Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer.
Hu HL; Wang CF; Wei XH; Lv JX; Cao XH; Shi YY; Han LF; Zhang YN
Int J Clin Exp Pathol; 2019; 12(3):1015-1021. PubMed ID: 31933913
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.
Pan H; Pan J; Song S; Ji L; Lv H; Yang Z
Front Oncol; 2021; 11():670041. PubMed ID: 33898326
[TBL] [Abstract][Full Text] [Related]
13. Erratum: ACAT2 Promotes Cell Proliferation and Associates with Malignant Progression in Colorectal Cancer [Corrigendum].
Onco Targets Ther; 2021; 14():4641-4643. PubMed ID: 34511933
[TBL] [Abstract][Full Text] [Related]
14. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.
Du H; Chen Y; Hou X; Huang Y; Wei X; Yu X; Feng S; Wu Y; Zhan M; Shi X; Lin S; Lu L; Yuan S; Sun L
Cell Death Dis; 2017 Oct; 8(10):e3143. PubMed ID: 29072684
[TBL] [Abstract][Full Text] [Related]
15. PLOD2 in cancer research.
Du H; Pang M; Hou X; Yuan S; Sun L
Biomed Pharmacother; 2017 Jun; 90():670-676. PubMed ID: 28415047
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Dissecting the Role of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer.
Zhang J; Shan B; Lin L; Dong J; Sun Q; Zhou Q; Chen J; Han X
Front Cell Dev Biol; 2021; 9():812770. PubMed ID: 34957127
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum: MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis.
Zhang X; He X; Li Y; Xu Y; Chen W; Liu X; Hu X; Xiong L; Xu X
Front Mol Biosci; 2021; 8():826905. PubMed ID: 35004862
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum to "System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma".
Xu JH; Guan YJ; Qiu ZD; Zhang X; Zi LL; Zhou Y; Chen C; Yu J; Zhang YC; Wang WX
Oxid Med Cell Longev; 2022; 2022():9875295. PubMed ID: 35237387
[TBL] [Abstract][Full Text] [Related]
19. Targeted Demethylation of the PLOD2 mRNA Inhibits the Proliferation and Migration of Renal Cell Carcinoma.
Cao C; Ma Q; Huang X; Li A; Liu J; Ye J; Gui Y
Front Mol Biosci; 2021; 8():675683. PubMed ID: 34179084
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum to "Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma".
Dai XM; Huang T; Yang SL; Zheng XM; Chen GG; Zhang T
Dis Markers; 2017; 2017():3765279. PubMed ID: 29085181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
